According to the Smart Finance app, Akeso Biopharma (09926) is up nearly 5%, up 4.83% as of press time, at HKD 40.15, with a turnover of HKD 0.224 billion.

Huafu Securities pointed out that as IO's new generation cornerstone drugs, Yivoyib and Cardunireligado monoclonal antibodies fully borrowed the 'king-making road' of K drugs in clinical development strategy, which is narrow before wide, occupy a large share of the broad indication, expand the cancer species, and early adjuvant therapy. The bank pointed out that the approved indications for the treatment of lung cancer EGFR TKI resistance are of significant clinical significance, and the positive results marked the biggest uncertainty in the AK112 development success rate.

Guolian Securities issued a research report stating that Akeso Biopharma is the first domestic enterprise to commercialize domestic bispecific antibodies, and is positioned in the fields of oncology, bispecific antibodies, self-immunity, and lipid-lowering. The company's existing products include two monoclonal antibody drugs, Cadrulizumab and Pamiparib, among which Cadrulizumab, the first cervical cancer drug, has an annual sales revenue of over CNY 1 billion; and Yivoyi, a lung cancer drug under development, has an external authorization payment of USD 0.5 billion and is expected to be listed domestically in 2024 and subsequently overseas. Two self-immunity and lipid-lowering drugs are expected to be approved for listing in non-tumor fields in 2024.